



**PRESS RELEASE**

October 7, 2021

Gothenburg

## Conference call on Interim Report

**Invitation to attend XVIVO's conference call regarding the presentation of the interim report July - September 2021. The presentation will be held in English.**

Time: Thursday, October 21, 2021 at 2.00 p.m. CET

Information regarding the conference can be found under the following link:

**<https://onlinexperiences.com/Launch/QReg/ShowUUID=07001B8B-3391-4BA9-8F3E-BBE54EDF834E>**.

Phone numbers to the conference:

Sweden: +46 856642651 PIN: 13466713#

UK: +44 3333000804 PIN: 13466713#

US: +1 6319131422 PIN: 13466713#

Conference name: XVIVO Group Interim Report Q3, conference ID: EV00128347

Participants from XVIVO:

Dag Andersson, CEO

Kristoffer Nordström, CFO

The press release for XVIVO's interim report July-September 2021 will be released on October 21, 2021 at 7:30 a.m. CET.

Before the conference call, slides will be available at the company web page, **<https://www.xvivoperfusion.com/corporate/financial-presentations/earnings-calls/>**

October 7, 2021

Gothenburg

XVIVO Perfusion AB (publ)

**For further information, please contact:**

---

Dag Andersson, CEO, +46 76 643 30 31, e-mail: [dag.andersson@xvivogroup.com](mailto:dag.andersson@xvivogroup.com)

Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: [kristoffer.nordstrom@xvivogroup.com](mailto:kristoffer.nordstrom@xvivogroup.com)

## **About Us**

---

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website [www.xvivogroup.com](http://www.xvivogroup.com).

## **Attachments**

---

**Conference call on Interim Report**